2013 Fiscal Year Final Research Report
Augmentation of ADCC activity according to FcR polymorphisms in patients with gastric cancer who receive monoclonal antibody therapy
| Project/Area Number |
23591934
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Yamaguchi University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YOSHIMURA Kiyoshi 山口大学, 医学部附属病院, 助教 (30346564)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 胃癌 / 大腸癌 / ADCC活性 / 抗体医薬 / Fc受容体 / 遺伝子多型 / レンチナン |
|---|
| Research Abstract |
Monoclonal antibodies are widely used for patients with gastric or colorectal cancer. These drugs have direct effect on the tumor cells, however modulation of the immune response could be another important mechanism. Antibody dependent cellular cytotoxicity (ADCC) mediated through the receptor (FcR) of the antibodies carried by immune cells plays an important role in the antitumor effect of the antibody. In this study, we confirmed that both monoclonal antibodies of trastuzumab and cetuximab had ADCC activity, however immunomodulator lentinan showed no augmentation of ADCC. Genetic features of FcR polymorphisms may be associated with the outcome of cancer patients treated with monoclonal antibodies.
|
